Regulatory Sandboxes for AI in Drug Development and Clinical Trials
Regulator
Depth/Specificity of AI Sandbox
(focus on AI in drug development)
Scope of AI Experimentation
(breadth of permitted AI
Special Purpose Acquisition Companies in Healthcare and Biotech: A Mid-2025 Market Appraisal
The landscape for Special Purpose Acquisition Companies (SPACs) within the healthcare and biotechnology sectors in mid-2025 presents a complex, dual
The weekly term sheet (32)
Global pharmaceutical and biotech deals remain subdued during August week
The week of August 4-9, 2025 marked an unusually quiet
The great AI medicine show
In the late 19th century, traveling medicine shows peddled cure-all elixirs with flamboyant claims. Today’s equivalent in biotech is
Company of the week: BridgeBio Pharma (BBIO)
BridgeBio Pharma stands at a critical inflection point in its evolution from development-stage biotech to commercial pharmaceutical company. With the
Fund of the week: LifeArc
Overview and Financial Model
LifeArc is a UK-based medical research charity with a unique financial model, operating more like an
Intel’s Advances in Biotech: Genomics and Drug Discovery with AI Accelerators (2025)
Habana Gaudi2 and Gaudi3 Accelerators
Intel’s Gaudi2 (2022) and Gaudi3 (2024) AI accelerators target training of large models with
AMD's Expanding Role in AI for Biotechnology: A Comprehensive Analysis
Advanced Micro Devices (AMD) has emerged as a significant challenger to NVIDIA's long-standing dominance, pursuing an aggressive strategy
Nvidia’s Expanding Footprint in Biotech: A Hardware-Centric Analysis
The convergence of artificial intelligence (AI), accelerated computing hardware, and vast biological datasets is transforming healthcare and biotech into a
The weekly term sheet (31)
Global pharmaceutical and biotech deals surge with $15+ billion in transactions
The pharmaceutical and biotechnology sectors witnessed significant deal activity
